You are here

New Dose of Fluzone Quadrivalent Approved for Children 6 to 35 Months of Age

New Influenza Vaccine Option Could Streamline Immunization Efforts

The FDA has approved the use of Sanofi Pasteur’s 0.5-mL dose of Fluzone® Quadrivalent (influenza vaccine) for children aged 6 to 35 months old. The 0.5-mL dose, as well as the 0.25-mL dose, will be available for the upcoming 2019–2020 season for this expanded age range.

Fluzone Quadrivalent influenza vaccine is indicated for active immunization for the prevention of influenza caused by influenza A subtype viruses and type B virus(es) in the vaccine. Approval was based on data from a phase 4 safety and immunogenicity study in approximately 2,000 children. No new safety concerns were observed and the 0.5-mL dose induced a robust immune response.

Fluzone Quadrivalent should not be given to anyone who has had a severe allergic reaction to any component of the vaccine, including egg or egg products, or after a previous dose of the vaccine. Also, it should not be given to anyone who has experienced a severe allergic reaction after a previous dose of any influenza vaccine.

The most common side effects in children include pain, redness, and swelling where the shot is administered; muscle aches, fatigue, and headache. In young children, side effects include irritability, abnormal crying, drowsiness, appetite loss, vomiting, and fever.

Source: BioSpace, January 23, 2019

Recent Headlines

NY Hospitals Required to Implement Protocols in Suspected Cases
Presence of BOK Protein Key for Positive Treatment Response
Patient Access to Inhaler Use Data Could Improve Asthma Management
Overall Survival 4.3 Months’ vs. 1.5 Months for Traditional Regimens
Primary Immunodeficiencies Affect 250,000 People in U.S.
More Than 25% of Patients Responded to Xpovio/Dexamethasone Combo
Attacks Cancerous Cells, Leaves Healthy Tissues Alone
Moderates Pre-diabetes Progression, Reduces Cholesterol Levels